This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gillmore, R. Articles by Stauss, H. J. Search for Related Content PubMed PubMed Citation Articles by Gillmore, R. Articles by Stauss, H. J.

Detection of Wilms' Tumor Antigen–Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer

Authors' Affiliations: ¹ Department of Immunology and Molecular Pathology, Royal Free Hospital; Departments of ² Hematology, ³ Histopathology, ⁴ Immunology, and ⁵ Cancer Medicine, Imperial College London, Hammersmith Hospital; Departments of ⁶ Surgery and ⁷ Histopathology, St Mary's NHS Trust, London, United Knigdom

Requests for reprints: Hans J. Stauss, Department of Immunology and Molecular Pathology, Royal Free Hospital, Pond Street, London NW3 2QG, United Kingdom. Phone: 44-20-7794-0500, ext. 3321; Fax: 44-20-7433-1943; E-mail: h.stauss{at}medsch.ucl.ac.uk.

Purpose: The Wilms' tumor antigen (WT1) is overexpressed in 90% of breast tumors and, thus, is a potential target antigen for the immunotherapy of breast cancer. We have tested the working hypotheses that WT1 can be immunogenic in patients with breast cancer and can stimulate CTL of sufficient avidity to kill tumor cells.

Experimental Design: Paired tumor-draining lymph node and peripheral blood samples were analyzed from five HLA-A2-positive patients with stage I/II breast cancer. Fluorescent HLA-A*0201/WT1 tetramers were used to quantify WT1-specific CTL and the functional capacity of the CTL was assessed using cytotoxicity assays and intracellular cytokine staining.

Results: WT1 tetramer–binding T cells expanded from all lymph node samples but none of the corresponding peripheral blood samples. Functional assays were carried out on T cells from the patient who had yielded the highest frequency of HLA-A*0201/WT1 tetramer–positive cells. The cytotoxicity assays showed WT1 peptide–specific killing activity of the CTL, whereas intracellular cytokine staining confirmed that the tetramer–positive T cells produced IFN- after stimulation with WT1 peptide. These WT1-specific T cells killed HLA-A2-positive breast cancer cell lines treated with IFN- but no killing was observed with untreated tumor cells.

Conclusions: These results show that WT1-specific CTL can be expanded from the tumor-draining lymph nodes of breast cancer patients and that they can display peptide-specific effector function. However, the CTL only killed IFN--treated tumor targets expressing high levels of HLA-A2 and not tumor cells with low HLA expression. This suggests that induction of autologous WT1-specific CTL may offer only limited tumor protection and that strategies that allow a high level of peptide/MHC complex presentation and/or improve CTL avidity may be required.

This article has been cited by other articles:

				K. Rezvani, A. S. M. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, and A. J. Barrett Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood, January 1, 2008; 111(1): 236 - 242. [Abstract] [Full Text] [PDF]

				J. Nitcheu-Tefit, M.-S. Dai, R. J. Critchley-Thorne, F. Ramirez-Jimenez, M. Xu, S. Conchon, N. Ferry, H. J. Stauss, and G. Vassaux Listeriolysin O Expressed in a Bacterial Vaccine Suppresses CD4+CD25high Regulatory T Cell Function In Vivo J. Immunol., August 1, 2007; 179(3): 1532 - 1541. [Abstract] [Full Text] [PDF]

				R. J. May, T. Dao, J. Pinilla-Ibarz, T. Korontsvit, V. Zakhaleva, R. H. Zhang, P. Maslak, and D. A. Scheinberg Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells Clin. Cancer Res., August 1, 2007; 13(15): 4547 - 4555. [Abstract] [Full Text] [PDF]

				A. M. Asemissen, U. Keilholz, S. Tenzer, M. Muller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, et al. Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1 Clin. Cancer Res., December 15, 2006; 12(24): 7476 - 7482. [Abstract] [Full Text] [PDF]